{"id":"W4415654614","doi":"10.1177/13524585251389797","title":"Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis","year":2025,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Janssen Pharmaceuticals; EMD Serono; MedDay Pharmaceuticals; Siemens Healthineers; Schweizerische Multiple Sklerose Gesellschaft; Eisai; Bundesministerium für Bildung und Forschung; Atara Biotherapeutics; National Institutes of Health; Mylan; TG Therapeutics; Novartis Pharmaceuticals Corporation; Multiple Sclerosis Society; European Committee for Treatment and Research in Multiple Sclerosis; Grifols; F. Hoffmann-La Roche; Alexion Pharmaceuticals; Bayer HealthCare; Novartis Pharma; European Commission; Eli Lilly and Company; U.S. Department of Defense; Multiple Sclerosis International Federation; Gemeinnützige Hertie-Stiftung; Sanofi; Neuraxpharm; Teva Pharmaceutical Industries; Novartis; Celgene; Biogen; Deutsche Forschungsgemeinschaft; Genentech; National Multiple Sclerosis Society; GlaxoSmithKline; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Multiple sclerosis; Disease; Central nervous system disease; Degenerative disease; Amyotrophic lateral sclerosis; Clinical neurology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00599404,0.0007659606,0.0005635389,0.0009459863,0.0003509143,0.001016626,0.0005841447,0.0009567965,0.001429957],"category_scores_gemma":[0.009521091,0.0002331134,0.000322665,0.0004193334,0.0006969084,0.0003834277,0.0004618761,0.0007571497,0.0008465755],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005610061,"about_ca_system_score_gemma":0.0004575804,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005015088,"about_ca_topic_score_gemma":0.000719243,"domain_scores_codex":[0.9970233,0.001133124,0.0002152153,0.0004382373,0.001035046,0.0001549554],"domain_scores_gemma":[0.9948261,0.001731879,0.001477762,0.0005071021,0.001070533,0.000386523],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007329024,0.001339735,0.8807535,0.0002589169,0.0002234587,0.0002923821,0.0005108205,0.001084329,0.0671294,0.0003196374,0.001178778,0.03958],"study_design_scores_gemma":[0.000713973,0.0183704,0.8463376,0.0001920443,0.0004466735,0.003186279,0.0003180808,0.01104312,0.1137835,0.0006020908,0.004931528,0.00007459861],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9796696,0.002428962,0.01056541,0.000294049,0.0001020747,0.0006517935,0.00136367,0.0002876957,0.004636766],"genre_scores_gemma":[0.9945382,0.0001225117,0.004146243,0.0001052732,0.00004464027,0.0001433315,0.0005030225,0.00001068488,0.0003859996],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00599404,"threshold_uncertainty_score":0.0316999,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1114129641189541,"score_gpt":0.3431834111194926,"score_spread":0.2317704470005386,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}